Emicizumab prophylaxis for the treatment of people with moderate or mild Hemophilia A without Factor VIII inhibitors: results from the primary analysis of the HAVEN 6 study

J. Oldenburg,Cédric Hermans, C Negrier,Michaela Lehle,Pratima Chowdary,Olivier Catalani,Víctor Jiménez‐Yuste,Christophe Schmitt,Giuliana Ventriglia, Jerzy Windyga,Anna Kiialainen, R. d'Oiron,Paul Moorehead, S Koparkar,Vanda Teodoro, D A Shapiro

Hamostaseologie（2023）

引用 0|浏览3

暂无评分

摘要

Introduction Emicizumab is a bispecific monoclonal antibody that substitutes for missing activated factor (F)VIII in people with hemophilia A (HA). This primary analysis ofHAVEN 6 (NCT04158648) aims to assess safety and efficacy of emicizumab prophylaxis in people with non-severe HA without FVIII inhibitors.

查看译文

关键词

factor viii inhibitors,hemophilia,prophylaxis,treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要